LTRN
Lantern Pharma IncNASDAQ
Healthcare • Biotechnology
$0.57+6.75%
Close Nov 6, 2026
- Market cap
- $7.06M
- 1 month
- -31.6%
- 3 months
- -79.8%
- 1 year
- -84.0%
- 52-week range
- $0.53$4.17
- Dividend
- No dividends on record
- Short interest
- 3.9% of float388.7K shares · settled Oct 15, 2026 · -20.0% since Sep 30, 2026 · FINRA
Fundamentals · trailing 12 months to Jun 30, 2026
- Revenue
- —
- Net income
- -$18.65M
- Free cash flow
- -$14.08M
- Book value
- —
- Total debt
- $39.72K
- P/E
- —
- Price / sales
- —
- Price / book
- —
- FCF yield
- -199.5%
- Net margin
- —
EODHD (TTM) · as of Nov 6, 2026
End-of-day close from stored market data, not a live quote.
About Lantern Pharma Inc
Lantern Pharma Inc. focuses on the discovery and development of oncology drug in India. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1a clinical trial for the treatment of advanced or metastatic solid tumors, or unresectable or recurrent GBM, solid tumor, such as pancreatic,
Read more
breast, bladder, and lung cancers, as well as glioblastoma and other central nervous system (CNS) cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin's lymphomas, including mantle cell lymphoma and double hit lymphoma. The company also develops STAR-001, which is in preclinical development for the treatment of glioblastoma, brain metastases, atypical teratoid rhabdoid tumors, and several rare pediatric CNS cancers. In addition, it provides ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. The company has a strategic AI-driven collaboration with Oregon Therapeutics to optimize the development of its first-in-class protein disulfide isomerase inhibitor drug candidate XCE853 in novel and targeted cancer indications; a collaboration agreement with TTC Oncology, which focuses on the drug development of TTC-352 to treat patients with metastatic ER+ breast cancer; and a collaboration agreement with Actuate Therapeutics, Inc. that focuses on the development of compounds for use in the treatment of cancer and inflammatory diseases leading to fibrosis. The company was incorporated in 2013 and is headquartered in Dallas, Texas.
- Website
- lanternpharma.com
- Headquarters
- Dallas, TX, United States
- Employees
- 16
- Listed
- Jun 11, 2020
- Fiscal year ends
- December
Company profile from EODHD, stored Nov 3, 2026.
Quarterly results
The last 8 fiscal quarters as reported (EODHD). Year over year compares the same quarter a year earlier.
| Quarter | Revenue | YoY | Gross margin | Op. income | Net income |
|---|---|---|---|---|---|
| Jun 2026filed Aug 14, 2026 | — | — | — | -$3.5M | -$7.1M |
| Mar 2026filed May 15, 2026 | — | — | — | -$3.4M | -$3.3M |
| Dec 2025filed Mar 30, 2026 | — | — | — | -$4.2M | -$4.1M |
| Sep 2025filed Nov 12, 2025 | — | — | — | -$4.3M | -$4.2M |
| Jun 2025filed Aug 13, 2025 | — | — | — | -$4.7M | -$4.3M |
| Mar 2025filed May 15, 2025 | $100.7K | — | — | -$4.8M | -$4.5M |
| Dec 2024filed Mar 27, 2025 | $100.7K | -61.4% | — | -$5.9M | -$5.9M |
| Sep 2024filed Nov 7, 2024 | — | — | — | -$5.2M | -$4.5M |
Fiscal years · last 6
| Fiscal year | Revenue | YoY | Gross margin | Op. income | Net income |
|---|---|---|---|---|---|
| Dec 2025filed Mar 30, 2026 | — | — | — | -$18.0M | -$17.1M |
| Dec 2024filed Mar 27, 2025 | — | — | — | -$22.2M | -$20.8M |
| Dec 2023filed Mar 18, 2024 | — | — | — | -$17.9M | -$16.0M |
| Dec 2022filed Mar 20, 2023 | — | — | — | -$14.4B | -$14.3B |
| Dec 2021filed Mar 10, 2022 | — | — | — | -$12.6M | -$12.4M |
| Dec 2020filed Mar 10, 2021 | — | — | — | -$5.9M | -$5.9M |
Short-interest history
FINRA reports open short positions for a settlement date. The publication date is later. These are reported positions, with a separate date for each observation.
Compare the reported short exposure around the dates you bought, sold or watched LTRN. A long position benefits from price rises; a short position benefits from falls. A change in these counts does not predict either move.
Settlement Oct 15, 2026
388,655 shares short
-97,095 shares (-20%) vs Sep 30, 2026
3.9% of the stored float. Published Oct 26, 2026.
Settlement Sep 30, 2026
485,750 shares short
-72,231 shares (-12.9%) vs Sep 15, 2026
4.9% of the stored float. Published Oct 9, 2026.
Settlement Sep 15, 2026
557,981 shares short
-6,651 shares (-1.2%) vs Aug 31, 2026
5.8% of the stored float. Published Sep 24, 2026.
Settlement Aug 31, 2026
564,632 shares short
-128,402 shares (-18.5%) vs Aug 14, 2026
Share of float unavailable. Published Sep 10, 2026.
Settlement Aug 14, 2026
693,034 shares short
-153,338 shares (-18.1%) vs Jul 31, 2026
Share of float unavailable. Published Aug 25, 2026.
Settlement Jul 31, 2026
846,372 shares short
-98,844 shares (-10.5%) vs Jul 15, 2026
Share of float unavailable. Published Aug 11, 2026.
Change = this settlement’s shares short − the previous recorded settlement’s shares short; percentage change divides by that earlier count. A zero earlier count has no percentage change. Split-spanning counts are left uncompared. Float percentages use the stored settlement observation, not today’s float.
Source: stored FINRA equity short-interest records, up to six settlements from the last 240 days. FINRA data and reporting dates · How to read short interest
Dividends and stock splits
See the recorded cash amounts and dates behind LTRN’s income, and the splits that change its share count. Dates below are stored event records, not confirmation of a payment to your account.
Cash-dividend records
No qualified cash-dividend records are stored. This does not establish that the company pays no dividend.
Up to six Polygon cash-dividend events, including recorded ex-dates within the next 120 days. Amounts retain their recorded currency and decimal precision. Historical amounts are not restated to a common split basis, annualized, or converted to dollars.
For a long holding, compare the ex-date with when you held the shares and check the pay date against your broker’s cash history. Owning the stock today does not establish past entitlement. For a short holding, a dividend can create a payment obligation to the share lender.
Ex-dates and special dividend rules · Short-sale dividend obligations · Dividend data definitions
Split history
No qualified split events are stored. This does not establish that the stock has never split.
Up to six stored split dates through Nov 7, 2026. Equivalent vendor ratios are combined; conflicting ratios are left out. This history may be incomplete.
A split changes the share count and per-share price basis; it does not by itself add investment value. Put your holding’s earlier and later share counts on the same basis before comparing them. This applies to both long shares and shares owed on a short position.
How stock splits workPortfolio context
Sign in to see your position size
We’ll show you if LTRN is in your portfolio and how much it contributes.
Sign inMarket context
Loading market dates
Smart money context
Holder IQ: MEDIUM
6 smart-money holders: institutions with a high Holder IQ
Q2 2026, filed Oct 29, 2026
Insider context
Sentiment: unknown
No recent insider trades detected.
Read the insider context evidence
What it means for you
Sign in to read your holdings or watchlist context. No personal position or direction is inferred.
What happened
No directional recent-activity label is available. This context label is separate from the scored insider signal read.
Why it can matter
A count of reported activity describes a sample, not purchase conviction, an insider’s intent or a future price move. Neutral is not an all-clear, and absent direction is not neutral evidence.
How we got this
The current context rule reads at most 50 nonduplicate issuer/share-class records filed in the last 90 days. It counts a bullish direction or purchase code P toward bullish, and a bearish direction or sale code S toward bearish. A side must exceed the opposite count by more than two to set its label; otherwise nonzero directional counts produce neutral. Calculation unavailable for this saved label: its counts, exact records, as-of time and rule version are not supplied here. Do not substitute the separate scored read’s different window or denominator.
Where the data comes from
Stored SEC Forms 3/4/5 insider-signal records, ordered by filing date with amendment duplicates excluded. Filing date is not transaction date. The last-trade line locates recent reported activity; it does not date or reconstruct the complete count.
Red flags: 0
Read the insider context evidence
What it means for you
Sign in to read your holdings or watchlist context. No personal position or direction is inferred.
What happened
No directional recent-activity label is available. This context label is separate from the scored insider signal read.
Why it can matter
A count of reported activity describes a sample, not purchase conviction, an insider’s intent or a future price move. Neutral is not an all-clear, and absent direction is not neutral evidence.
How we got this
The current context rule reads at most 50 nonduplicate issuer/share-class records filed in the last 90 days. It counts a bullish direction or purchase code P toward bullish, and a bearish direction or sale code S toward bearish. A side must exceed the opposite count by more than two to set its label; otherwise nonzero directional counts produce neutral. Calculation unavailable for this saved label: its counts, exact records, as-of time and rule version are not supplied here. Do not substitute the separate scored read’s different window or denominator.
Where the data comes from
Stored SEC Forms 3/4/5 insider-signal records, ordered by filing date with amendment duplicates excluded. Filing date is not transaction date. The last-trade line locates recent reported activity; it does not date or reconstruct the complete count.
Largest 13-F holders · Q2 2026
40 filers reported a long position in LTRN for Q2 2026. 13-F holdings are filed up to 45 days after the quarter ends.
The top 10 hold
73.6%
of the 2.9M shares 13-F filers reported
Moves vs Q1 2026
3 added4 trimmed
3 new
Net shares held
-23.1%
across the 7 holders with a comparable Q1 2026 book
| Rank | Holder | Value | Shares | Shares vs Q1 2026 |
|---|---|---|---|---|
| 1 | Empery Asset Management, LP | $3.5M · 842.7K shares | 842.7K | New |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | $1.8M · 425.1K shares | 425.1K | +28% |
| 3 | RENAISSANCE TECHNOLOGIES LLC | $1.2M · 291K shares | 291K | +150.9% |
| 4 | BIOS Capital Management, LP | $1M · 249.4K shares | 249.4K | -71.1% |
| 5 | GEODE CAPITAL MANAGEMENT, LLC | $428.9K · 102.8K shares | 102.8K | -7.9% |
| 6 | VANGUARD FIDUCIARY TRUST CO | $208.3K · 50K shares | 50K | +0.7% |
| 7 | CITADEL ADVISORS LLC | $199.7K · 47.9K shares | 47.9K | New |
| 8 | Westside Investment Management, Inc. | $199.5K · 47.9K shares | 47.9K | -4.4% |
| 9 | Quadrature Capital Ltd | $165.1K · 39.6K shares | 39.6K | New |
| 10 | NewEdge Advisors, LLC | $112.8K · 27K shares | 27K | -1.3% |
Sign in to see each holder’s Holder IQ, factor-adjusted Holder IQ and rank, and compare these holders with all scored filers. Available on every plan.
Sign in5% holder filings (13D / 13G)
Holders of more than 5% of LTRN file with the SEC within days. A 13D holder may seek to influence the company; a 13G holder is passive. Each holder’s latest filing from the last three years.
| Filed | Holder | % of class |
|---|---|---|
| Oct 13, 2026 | Empery Asset Management, LP13G · passive · amended | 4.99%under 5% |
| Jul 23, 2026 | SATTERFIELD THOMAS A JR13G · passive · amended | 7.6% |
| May 15, 2026 | Bios Equity Partners LP13D · activist · amended | 4.48%under 5% |
Get the Full Analysis for LTRN
Unlock detailed insider transactions, institutional holder changes, factor exposures, and personalized alerts. Start free with your own portfolio.